News articles about Spectranetics Corp (NASDAQ:SPNC) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Spectranetics Corp earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 45.665053768374 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Several research analysts recently issued reports on the company. Stifel Nicolaus lowered Spectranetics Corp from a “buy” rating to a “hold” rating and upped their target price for the company from $34.00 to $38.50 in a research report on Wednesday, August 9th. Needham & Company LLC lowered Spectranetics Corp from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. BidaskClub lowered Spectranetics Corp from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 10th. Guggenheim lowered Spectranetics Corp from a “buy” rating to a “neutral” rating in a research report on Friday, August 4th. Finally, Canaccord Genuity lowered Spectranetics Corp from a “buy” rating to a “hold” rating and upped their target price for the company from $37.00 to $38.50 in a research report on Monday, July 10th. Eleven analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $35.36.

Shares of Spectranetics Corp (NASDAQ SPNC) remained flat at $38.45 during mid-day trading on Wednesday. The stock had a trading volume of 1,728,937 shares. The company has a 50-day moving average of $37.28 and a 200 day moving average of $30.10. Spectranetics Corp has a 1-year low of $19.80 and a 1-year high of $38.55.

Spectranetics Corp (NASDAQ:SPNC) last posted its quarterly earnings data on Thursday, August 3rd. The medical equipment provider reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.27) by $0.29. Spectranetics Corp had a negative net margin of 32.93% and a negative return on equity of 194.18%. The company had revenue of $74.71 million for the quarter, compared to analyst estimates of $73.82 million. During the same quarter in the prior year, the business earned ($0.35) EPS. Spectranetics Corp’s revenue was up 10.3% compared to the same quarter last year. On average, analysts predict that Spectranetics Corp will post ($1.16) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Spectranetics Corp (SPNC) Receiving Somewhat Positive Press Coverage, Accern Reports” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/spectranetics-corp-spnc-receiving-somewhat-positive-press-coverage-accern-reports/1532583.html.

Spectranetics Corp Company Profile

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads.

Insider Buying and Selling by Quarter for Spectranetics Corp (NASDAQ:SPNC)

Receive News & Ratings for Spectranetics Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectranetics Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.